These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 7502428)

  • 1. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.
    Chodak G; Sharifi R; Kasimis B; Block NL; Macramalla E; Kennealey GT
    Urology; 1995 Dec; 46(6):849-55. PubMed ID: 7502428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
    Iversen P; Tyrrell CJ; Kaisary AV; Anderson JB; Van Poppel H; Tammela TL; Chamberlain M; Carroll K; Melezinek I
    J Urol; 2000 Nov; 164(5):1579-82. PubMed ID: 11025708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
    Tyrrell CJ; Iversen P; Tammela T; Anderson J; Björk T; Kaisary AV; Morris T
    BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
    Di Lorenzo G; Perdonà S; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Autorino R
    J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
    Blackledge G; Kolvenbag G; Nash A
    Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of bicalutamide in the treatment of prostate cancer].
    Stav SY; Segal G
    Harefuah; 2002 Apr; 141(4):379-83, 408, 407. PubMed ID: 12017896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
    McLeod DG; Iversen P; See WA; Morris T; Armstrong J; Wirth MP;
    BJU Int; 2006 Feb; 97(2):247-54. PubMed ID: 16430622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup.
    McLeod DG; See WA; Klimberg I; Gleason D; Chodak G; Montie J; Bernstein G; Morris C; Armstrong J
    J Urol; 2006 Jul; 176(1):75-80. PubMed ID: 16753373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years.
    Iversen P; McLeod DG; See WA; Morris T; Armstrong J; Wirth MP;
    BJU Int; 2010 Apr; 105(8):1074-81. PubMed ID: 22129214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
    Boccardo F; Rubagotti A; Conti G; Potenzoni D; Manganelli A; Del Monaco D
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):415-20. PubMed ID: 15838655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.
    Sugiono M; Winkler MH; Okeke AA; Benney M; Gillatt DA
    Prostate Cancer Prostatic Dis; 2005; 8(1):91-4. PubMed ID: 15711607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
    Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
    BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer.
    Gravina GL; Festuccia C; Galatioto GP; Muzi P; Angelucci A; Ronchi P; Costa AM; Bologna M; Vicentini C
    Urology; 2007 Oct; 70(4):728-33. PubMed ID: 17991545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.
    Iversen P; Wirth MP; See WA; McLeod DG; Klimberg I; Gleason D; Chodak G; Montie J; Tyrrell C; Wallace DM; Delaere KP; Lundmo P; Tammela TL; Johansson JE; Morris T; Carroll K;
    Urology; 2004 May; 63(5):928-33. PubMed ID: 15134983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
    Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
    Davis NB; Ryan CW; Stadler WM; Vogelzang NJ
    BJU Int; 2005 Oct; 96(6):787-90. PubMed ID: 16153201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.
    Iversen P; Tyrrell CJ; Kaisary AV; Anderson JB; Baert L; Tammela T; Chamberlain M; Carroll K; Gotting-Smith K; Blackledge GR
    Urology; 1998 Mar; 51(3):389-96. PubMed ID: 9510340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.